Uses and abuses of bisphosphonates.
暂无分享,去创建一个
[1] C. Löwik,et al. Tumour progression and angiogenesis in bone metastasis from breast cancer: new approaches to an old problem. , 2000, Cancer treatment reviews.
[2] Paul J. Williams,et al. Use of bisphosphonates for the treatment of bone metastasis in experimental animal models. , 1999, Cancer treatment reviews.
[3] G. Romieu,et al. A Dose‐Finding Study of Zoledronate in Hypercalcemic Cancer Patients , 1999, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[4] C. Rudenstam,et al. Efficacy of pamidronate in breast cancer with bone metastases: a randomized double-blind placebo controlled multicenter study. , 1999, Acta oncologica.
[5] G. Hortobagyi,et al. Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial. Protocol 18 Aredia Breast Cancer Study Group. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] J. Kanis,et al. Double-blind, randomised, placebo-controlled, dose-finding study of oral ibandronate in patients with metastatic bone disease. , 1999, Annals of oncology : official journal of the European Society for Medical Oncology.
[7] J. Kanis,et al. Current use of bisphosphonates in oncology. International Bone and Cancer Study Group. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] G. Hortobagyi,et al. Markers of bone resorption in patients treated with pamidronate. , 1998, European journal of cancer.
[9] D. Wallwiener,et al. Reduction in new metastases in breast cancer with adjuvant clodronate treatment. , 1998, The New England journal of medicine.
[10] Dunn,et al. A randomized trial of the effect of clodronate on skeletal morbidity in multiple myeloma , 1998, British journal of haematology.
[11] M. Rogers,et al. Overview of bisphosphonates , 1997, Cancer.
[12] C. Blomqvist,et al. Chemical castration induced by adjuvant cyclophosphamide, methotrexate, and fluorouracil chemotherapy causes rapid bone loss that is reduced by clodronate: a randomized study in premenopausal breast cancer patients. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] G. Hortobagyi,et al. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group. , 1996, The New England journal of medicine.
[14] J. Bonneterre,et al. Delay in progression of bone metastases in breast cancer patients treated with intravenous pamidronate: results from a multinational randomized controlled trial. The Aredia Multinational Cooperative Group. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] M. Piccart,et al. Use of bisphosphonates in cancer patients. , 1996, Cancer treatment reviews.
[16] M. Kovacs,et al. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group. , 1996, The New England journal of medicine.
[17] M. Laakso,et al. Randomised, placebo-controlled multicentre trial of clodronate in multiple myeloma , 1992, The Lancet.
[18] J. Hermans,et al. REDUCED MORBIDITY FROM SKELETAL METASTASES IN BREAST CANCER PATIENTS DURING LONG-TERM BISPHOSPHONATE (APD) TREATMENT , 1987, The Lancet.
[19] T. Powles,et al. Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.